Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AstraZeneca, Rigel Sign Drug Pact
by Lisa M. Jarvis
February 22, 2010
| A version of this story appeared in
Volume 88, Issue 8
AstraZeneca will pay $100 million up front for access to Rigel Pharmaceuticals’ fostamatinib, an oral spleen tyrosine kinase (STK) inhibitor that has passed Phase II trials to treat rheumatoid arthritis. Rigel could score another $345 million in milestones, as well as royalties, and up to $800 million in other payments if the drug reaches certain sales targets. AstraZeneca will take responsibility for Phase III studies of the drug, expected to begin in the second half of this year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter